Skip to content


Parsabiv (velcalcetide) is a protein pharmaceutical. Velcalcetide was first approved as Parsabiv on 2016-11-11. It has been approved in Europe to treat secondary hyperparathyroidism. It is known to target extracellular calcium-sensing receptor. Parsabiv's patents are valid until 2034-06-27 (FDA).
Trade Name Parsabiv
Common Name Etelcalcetide
Indication secondary hyperparathyroidism
Drug Class Peptides
Get full access now